2020 Fiscal Year Final Research Report
Study of Drug Resistance in Cancer Cells to Develop Molecular Target Drugs
| Project/Area Number |
17H05056
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (A)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Tokyo University of Pharmacy and Life Science |
|---|
Principal Investigator |
Satow Reiko 東京薬科大学, 生命科学部, 講師 (90469966)
|
|---|
| Project Period (FY) |
2017-04-01 – 2021-03-31
|
| Keywords | がん / 薬剤耐性 |
|---|
| Outline of Final Research Achievements |
"Drug resistance" is a major problem that hinders the remission of cancer, and it is necessary to develop a therapeutic method that overcomes drug resistance. So far, the principal investigator has identified a protein that is highly expressed in many types of cancer, and promotes the survival and drug resistance of various cancers. In this research project, we screened for small molecule compounds and found multiple compounds that inhibit the function of this factor. We also identified several proteins that bind to and control this factor.
|
| Free Research Field |
分子生物学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究課題において、がん特異的に高発現し様々な癌の生存や薬剤耐性を亢進させるタンパク質を阻害する低分子化合物を見出した。この低分子化合物は、メラノーマや薬剤耐性メラノーマに細胞死を誘導したが、正常ヒトメラノサイトや正常ヒトケラチノサイトには細胞死を誘導しなかった。これらのことから、同定した低分子化合物がメラノーマや薬剤耐性メラノーマに有効であると考えられる。また、このタンパク質の制御機構を明らかにすることでさらなる治療薬の開発につながる。
|
